MedTrace Logo

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

NCT07351786 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-01-20

No results posted yet for this study

Summary

This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.

Conditions

  • Diabetes (DM)
  • Retinopathy, Diabetic
  • Diabetic Retinopathy (DR)
  • Diabetic Retinopathy Associated With Type 2 Diabetes Mellitus

Sponsors & Collaborators

  • Sara A Belal

    lead OTHER

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-08-01
Completion
2026-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07351786 on ClinicalTrials.gov